uniQure to Present Clinical Data from Study of AMT-060 in Hemophilia B at Upcoming ASH Meeting
uniQure, a company specializing in human gene therapy, will present clinical data from a Phase 1/2 dose-escalating study of AMT-060 in adults with hemophilia B at the upcoming 58th American Society of Hematology Annual Meeting (ASH 2016), to be held in San Diego, Calif., in Dec.3-6. The…